R
Richard D. Moore
Researcher at Johns Hopkins University
Publications - 825
Citations - 56571
Richard D. Moore is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Population. The author has an hindex of 119, co-authored 774 publications receiving 51857 citations. Previous affiliations of Richard D. Moore include Harvard University & Stellenbosch University.
Papers
More filters
Journal ArticleDOI
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
Samuel Charache,Michael L. Terrin,Richard D. Moore,George J. Dover,Franca B. Barton,Susan V. Eckert,Robert P. McMahon,Duane Bonds +7 more
TL;DR: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year and Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect.
Journal ArticleDOI
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
Hasina Samji,Angela Cescon,Robert S. Hogg,Robert S. Hogg,Sharada P. Modur,Keri N. Althoff,Kate Buchacz,Ann N. Burchell,Mardge H. Cohen,Kelly A. Gebo,M. John Gill,Amy C. Justice,Gregory D. Kirk,Marina B. Klein,P. Todd Korthuis,Jeffrey N. Martin,Sonia Napravnik,Sean B. Rourke,Timothy R. Sterling,Michael J. Silverberg,Stephen G. Deeks,Lisa P. Jacobson,Ronald J. Bosch,Mari M. Kitahata,James J. Goedert,Richard D. Moore,Stephen J. Gange +26 more
TL;DR: A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.
Journal ArticleDOI
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more
TL;DR: The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.
Journal ArticleDOI
Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration
TL;DR: It is demonstrated that a high peak concentration relative to the MIC for the infecting organism is a major determinant of the clinical response to aminoglycoside therapy.
Journal ArticleDOI
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
TL;DR: The data indicate that use of ritonavir may increase risk of severe hepatotoxicity, and does not support withholding protease inhibitor therapy from persons coinfected with hepatitis B or C virus.